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Abstract
Gut invasive aspergillosis is an extremely rare infection in immunocompromised patients. The goal of this retrospective multicentre
study is to report on cases of gut aspergillosis in haematology patients, including clinical presentation, risk factors, and outcome.
Twenty-one patients from nine centres were identiﬁed. Eight had isolated gut aspergillosis, with no evidence of other infected sites, and
13 had disseminated aspergillosis. Thirteen patients had acute leukaemia. Nine were allogeneic stem cell transplant recipients. Clinical
symptoms and imaging were poorly speciﬁc. The galactomannan antigenaemia test result was positive in 16/25 (64%) patients, including
in four of the eight cases of isolated gut aspergillosis. Five of 21 patients had a dietary regimen rich in spices, suggesting that, in these
cases, food could have been the source of gut colonization, and then of a primary gut Aspergillus lesion. The diagnosis was made post-
mortem in six patients. The mortality rate in the remaining patients at 12 weeks was 7/15 (47%). Gut aspergillosis is probably misdiag-
nosed and underestimated in haematology patients, owing to the poor speciﬁcity of symptoms and imaging. Patients with a persistently
positive galactomannan antigenaemia ﬁnding that is unexplained by respiratory lesions should be suspected of having gut aspergillosis in
the presence of abdominal symptoms, and be quickly investigated. In the absence of severe abdominal complications leading to surgery
and resection of the lesions, the optimal treatment is not yet deﬁned.
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Introduction
Invasive aspergillosis (IA) is a life-threatening infection in
immunocompromised patients, mainly in acute leukaemia and
allogeneic haematopoietic stem cell transplant (HSCT) recipi-
ents [1]. The frequency of IA has obviously increased during
the last 20 years, as a consequence of the use of more effec-
tive, but also more toxic, chemotherapy and immunosuppress-
ing regimens, besides the growing number of HSCT cases [1].
Aspergillosis mainly involves the lower respiratory tract
and the sinuses. Other sites of infection are rarely observed,
except in case of dissemination [3–6].
Gut aspergillosis, either isolated or in the setting of
disseminated infection, has been occasionally reported in the
literature [2]. The largest report of digestive fungal infec-
tion—Aspergillus or Candida—was an autopsy series of
patients with haematological diseases [3], whereas the ﬁrst
case in a living patient was reported in 1985 after a right
colostomy in a haematology patient [4]. In a review of two
personal cases and eight cases of the literature, Eggiman et al.
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[5] have pointed out some characteristic features of IA of
the digestive tract, suggesting that the gut could be a portal
of entry for Aspergillus in immunocompromised patients.
Following three cases over 8 years in the haematology
department of Henri Mondor Hospital, we were interested
in collecting data from other centres. The goal of this retro-
spective multicentre study was to report on the clinical pre-
sentation, risk factors and outcome of gut aspergillosis in
haematology patients.
Methods
This was a multicentre retrospective study. In April 2009,
we sent a questionnaire to 13 haematology centres in France
and to four centres in Belgium and Switzerland. Nine of
these 17 centres had seen at least one case of gut aspergillo-
sis over the last 13 years and agreed to participate. The
study design was approved by the Comite´ de Protection des
Personnes Ile de France IX.
We elaborated a questionnaire to collect data anony-
mously. It was ﬁlled in from the medical chart, either by the
local investigator, or by the ﬁrst author. Inclusion criteria
were [1] haematological disease, including aplastic anaemia,
and [2] proven gut aspergillosis, diagnosed either pre-mor-
tem or post-mortem. Isolated liver or spleen localizations
were excluded, as well as cases documented only by PCR on
tissue, without histological ﬁndings of mould infection.
As the European Organization for Research and Treatment
of Cancer/Mycoses Study Group (EORTC/MSG) does not pro-
pose any criteria for a diagnosis of probable gut aspergillosis
[6], we collected data only from patients with proven disease,
documented through mucosal alteration and tissue invasion in
a biopsy specimen (obtained by endoscopy or surgery) or by
autopsy. Only patients with tissue culture-proven aspergillosis,
or with gut biopsy specimens showing tissue invasion by
ﬁlamentous fungi suggestive of Aspergillus and a positive serum
galactomannan (GM) antigenaemia test ﬁnding (ratio of ‡0.5)
were selected. The criteria of Segal et al. [7] were used to
assess the response to treatment at 12 weeks after the diagno-
sis. Patients were considered to have an isolated gut aspergillo-
sis if the available investigations performed did not show any
other focus consistent with probable or deﬁnite (biopsy-pro-
ven) aspergillosis according to the EORTC/MSG criteria [6].
Patients with at least one other lesion outside the gut were
considered to have disseminated aspergillosis.
Patients
Twenty-one patients were included. One patient (patient 3)
has been previously reported [8]. Fifteen patients were from
France, two from Switzerland, and four from Belgium. The
mean age of patients was 48 years (range: 18–70 years).
There were 12 females and nine males. The underlying dis-
ease was acute leukaemia in 13, acceleration of chronic mye-
loid leukaemia in two, lymphoma in two, myeloma in three,
and myelodysplastic syndrome in one. Nine patients had
received an allogeneic HSCT, ﬁve from a human leukocyte
antigen-identical donor, three from an unrelated donor, and
one from a cord blood. The conditioning regimens were
classiﬁed according to the European Group for Blood and
Marrow Transplantation recommendations, as either a stan-
dard or a reduced-intensity conditioning regimen [9]. Four
HSCT patients were transplanted with a standard regimen,
and ﬁve with a reduced-intensity conditioning regimen. Thir-
teen of 21 patients (57%) were neutropenic at the time of
diagnosis. Eleven patients had received a recent course of
high-dose cytosine arabinoside. Twelve patients were receiv-
ing (n = 6) or had received (n = 6) steroids within the last
60 days. The characteristics of the patients are presented in
Table 1.
Results
Of the 21 patients, 14 were febrile at the time of diagnosis. The
clinical presentation included diarrhoea in ten, abdominal pain
in 17, gut haemorrhage in seven, intestinal occlusion in six, and
perforation in one. Imaging of the abdomen—echography,
computed tomography (CT) and/or magnetic resonance
imaging—was performed in 14 cases: two ﬁndings were
normal, and the others were suggestive of gut abnormalities
(isolated or diffuse oedema and thickening of intestinal wall),
or only intestinal dilatation (Fig. 1).
Twenty patients had, concomitantly with the diagnosis of
gut aspergillosis, a chest CT scan, and 14 had a CT scan or
magnetic resonance imaging scan of the head. Eight patients
had an isolated gut lesion (patients 1–8), and 13 had dissemi-
nated disease (patients 9–21).
The gut symptoms, which were poorly speciﬁc, mostly led
to endoscopy when lesions were thought to be accessible;
only two of 17 patients with lower gut lesions (small bowel,
n = 9; colon or rectum, n = 8) were diagnosed by endos-
copy; the diagnosis was performed by endoscopy in ﬁve of
nine patients with upper gut lesions (oesophagus, n = 2;
stomach, n = 3; duodenum, n = 4). All patients had a gut
biopsy specimen that was positive for the presence of inva-
sive ﬁlamentous fungi (Fig. 2a,b) and additionally showed
ulcerative (n = 3), perforative (n = 3) or necrotic lesions
secondary to angio-invasive aspergillus embolism (n = 6).
In one case, histology showed a pattern of necrotizing
CMI Kazan et al. Gut aspergillosis in leukaemia patients 589
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 588–594
No claim to original US government works
T
A
B
L
E
1
.
C
li
n
ic
a
l
c
h
a
ra
c
te
ri
st
ic
s
o
f
th
e
2
1
p
a
ti
e
n
ts
w
it
h
g
u
t
a
sp
e
rg
il
lo
si
s
P
a
ti
e
n
t
n
o
.
A
g
e
(y
e
a
rs
)/
se
x
U
n
d
e
rl
y
in
g
d
is
e
a
se
T
re
a
tm
e
n
t
p
h
a
se
(t
y
p
e
o
f
c
o
n
d
it
io
n
in
g
if
H
S
C
T
)
N
e
u
tr
o
p
e
n
ia
<
5
0
0
/l
L
a
t
d
ia
g
n
o
si
s
S
it
e
o
f
g
u
t
in
fe
c
ti
o
n
O
th
e
r
si
te
s
in
fe
c
te
d
a
t
d
ia
g
n
o
si
s
D
ia
g
n
o
si
s
p
ro
c
e
d
u
re
M
y
c
o
lo
g
ic
a
l
c
u
lt
u
re
o
f
th
e
g
u
t
b
io
p
sy
sp
e
c
im
e
n
G
M
a
n
ti
g
e
n
a
e
m
ia
se
ru
m
te
st
a
t
ti
m
e
o
f
d
ia
g
n
o
si
s
(i
n
d
e
x
)
G
u
t
su
rg
e
ry
O
u
tc
o
m
e
a
t
1
2
w
e
e
k
s
a
ft
e
r
d
ia
g
n
o
si
s
1
5
6
/F
A
M
L
ﬁ
rs
t
p
h
as
e
In
d
u
ct
io
n
+
D
u
o
d
e
n
u
m
N
o
E
n
d
o
sc
o
p
y
P
o
si
ti
ve
N
o
t
av
ai
la
b
le
Y
e
s
Su
rv
iv
e
d
,
co
m
p
le
te
re
sp
o
n
se
2
6
2
/F
A
M
L
in
C
R
C
o
rd
b
lo
o
d
H
SC
T
d
ay
7
7
(R
IC
)
)
C
o
lo
n
N
o
E
n
d
o
sc
o
p
y
P
o
si
ti
ve
N
e
ga
ti
ve
N
o
Su
rv
iv
e
d
,
re
sp
o
n
se
n
o
t
e
va
lu
at
ed
3
5
4
/F
A
M
L
ﬁ
rs
t
p
h
as
e
In
d
u
ct
io
n
+
Sm
al
l
b
o
w
e
l
N
o
L
ap
ar
o
to
m
y
N
o
t
d
o
n
e
6
.4
Y
e
s
D
ie
d
in
th
e
o
p
e
ra
ti
n
g
th
e
at
re
4
2
4
/F
A
cc
e
le
ra
te
d
C
M
L
In
d
u
ct
io
n
+
C
o
lo
n
N
o
L
ap
ar
o
to
m
y
N
o
t
d
o
n
e
N
e
ga
ti
ve
Y
e
s
D
e
at
h
,
at
5
7
d
ay
s
af
te
r
d
ia
gn
o
si
s
5
1
9
/M
A
M
L
ﬁ
rs
t
p
h
as
e
In
d
u
ct
io
n
+
A
p
p
e
n
d
ix
N
o
L
ap
ar
o
to
m
y
N
e
ga
ti
ve
0
.6
Y
e
s
Su
rv
iv
e
d
,
co
m
p
le
te
re
sp
o
n
se
6
5
8
/F
A
L
L
in
C
R
C
o
n
so
lid
at
io
n
)
C
o
lo
n
N
o
E
n
d
o
sc
o
p
y
P
o
si
ti
ve
4
.2
N
o
Su
rv
iv
e
d
,
co
m
p
le
te
re
sp
o
n
se
7
5
1
/M
M
u
lt
ip
le
m
ye
lo
m
a
H
L
A
-i
d
en
ti
ca
l
H
SC
T
d
ay
3
0
3
(R
IC
)
)
St
o
m
ac
h
N
o
E
n
d
o
sc
o
p
y
P
o
si
ti
ve
N
e
ga
ti
ve
Y
e
s
D
e
at
h
,
at
1
7
d
ay
s
af
te
r
d
ia
gn
o
si
s
8
7
0
/F
A
M
L
in
R
C
C
o
n
so
lid
at
io
n
+
D
u
o
d
e
n
u
m
N
o
L
ap
ar
o
to
m
y
N
e
ga
ti
ve
0
.9
Y
e
s
Su
rv
iv
e
d
,
co
m
p
le
te
re
sp
o
n
se
9
6
2
/F
M
u
lt
ip
le
m
ye
lo
m
a
U
n
re
la
te
d
H
SC
T
d
ay
1
0
5
(s
ta
n
d
ar
d
)
+
Sm
al
l
b
o
w
e
l
L
u
n
g
(p
ro
b
ab
le
)
L
ap
ar
o
to
m
y
N
o
t
d
o
n
e
3
.6
Y
e
s
D
e
at
h
,
at
1
6
d
ay
s
af
te
r
d
ia
gn
o
si
s
1
0
5
2
/M
L
ym
p
h
o
m
a
ﬁ
rs
t
p
h
as
e
In
d
u
ct
io
n
+
Sm
al
l
b
o
w
e
l
L
u
n
g
(p
ro
b
ab
le
)
L
ap
ar
o
to
m
y
P
o
si
ti
ve
9
.9
Y
e
s
D
e
at
h
,
at
2
0
d
ay
s
af
te
r
d
ia
gn
o
si
s
1
1
2
3
/M
A
M
L
in
C
R
H
L
A
-i
d
en
ti
ca
l
H
SC
T
d
ay
6
2
(s
ta
n
d
ar
d
)
)
C
o
lo
n
L
u
n
g
(p
ro
ve
n
),
C
N
S
A
u
to
p
sy
N
o
t
d
o
n
e
1
N
o
–
1
2
4
4
/F
R
e
fr
ac
to
ry
ly
m
p
h
o
m
a
R
-D
H
A
P
)
St
o
m
ac
h
L
u
n
g
(p
ro
ve
n
),
C
N
S
E
n
d
o
sc
o
p
y
P
o
si
ti
ve
2
N
o
Su
rv
iv
e
d
,
p
ar
ti
al
re
sp
o
n
se
1
3
6
4
/M
A
M
L
ﬁ
rs
t
p
h
as
e
In
d
u
ct
io
n
+
Sm
al
l
b
o
w
e
l
L
u
n
g
(p
o
ss
ib
le
)
L
ap
ar
o
to
m
y
P
o
si
ti
ve
4
.6
Y
e
s
Su
rv
iv
e
d
,
co
m
p
le
te
re
sp
o
n
se
1
4
5
4
/F
A
M
L
re
la
p
se
Sa
lv
ag
e
+
Sm
al
l
b
o
w
e
l
L
u
n
g
(p
ro
b
ab
le
)
L
ap
ar
o
to
m
y
N
o
t
d
o
n
e
7
.7
Y
e
s
Su
rv
iv
e
d
,
co
m
p
le
te
re
sp
o
n
se
1
5
5
5
/F
A
M
L
re
la
p
se
Sa
lv
ag
e
+
Sm
al
l
b
o
w
e
l
L
u
n
g
(p
ro
b
ab
le
)
L
ap
ar
o
to
m
y
N
o
t
d
o
n
e
N
e
ga
ti
ve
Y
e
s
D
e
at
h
,
at
1
9
d
ay
s
af
te
r
d
ia
gn
o
si
s
1
6
3
8
/M
A
cc
e
le
ra
te
d
C
M
L
H
L
A
-i
d
en
ti
ca
l
H
SC
T
d
ay
1
3
7
(S
ta
n
d
ar
d
)
)
R
e
ct
u
m
L
u
n
g
(p
ro
ve
n
)
C
N
S,
liv
e
r,
sk
in
,
k
id
n
e
y,
h
e
ar
t,
sp
le
e
n
A
u
to
p
sy
P
o
si
ti
ve
0
.6
N
o
–
1
7
4
0
/F
A
M
L
re
la
p
se
H
L
A
-i
d
en
ti
ca
l
H
SC
T
d
ay
8
(R
IC
)
+
Sm
al
l
b
o
w
e
l
L
u
n
g
(p
ro
ve
n
)
A
u
to
p
sy
P
o
si
ti
ve
0
.5
N
o
–
1
8
6
5
/F
M
D
S
in
R
C
U
n
re
la
te
d
H
SC
T
d
ay
1
1
0
(R
IC
)
+
D
u
o
d
e
n
u
m
L
u
n
g
(p
ro
ve
n
)
A
u
to
p
sy
N
o
t
d
o
n
e
1
.4
N
o
–
1
9
1
8
/M
A
L
L
in
C
R
H
L
A
-i
d
en
ti
ca
l
H
SC
T
d
ay
1
1
7
(s
ta
n
d
ar
d
)
)
St
o
m
ac
h
L
u
n
g
(p
ro
ve
n
),
p
an
cr
e
as
,
p
e
ri
ca
rd
iu
m
,
ad
re
n
al
gl
an
d
A
u
to
p
sy
P
o
si
ti
ve
6
N
o
–
2
0
5
4
/M
M
u
lt
ip
le
m
ye
lo
m
a
U
n
re
la
te
d
H
SC
T
d
ay
5
4
(R
IC
)
)
D
u
o
d
e
n
u
m
L
u
n
g
(p
ro
b
ab
le
)
E
n
d
o
sc
o
p
y
N
o
t
d
o
n
e
0
.5
N
o
D
e
at
h
,
at
3
8
d
ay
s
af
te
r
d
ia
gn
o
si
s
2
1
5
5
/M
A
L
L
,
ﬁ
rs
t
p
h
as
e
In
d
u
ct
io
n
+
Sm
al
l
b
o
w
e
l
L
iv
e
r,
C
N
S
L
ap
ar
o
to
m
y
P
o
si
ti
ve
4
.5
Y
e
s
D
e
at
h
,
at
7
9
d
ay
s
af
te
r
d
ia
gn
o
si
s
A
L
L
,
ac
u
te
ly
m
p
h
o
b
la
st
ic
le
u
k
ae
m
ia
;
A
M
L
,
ac
u
te
m
ye
lo
id
le
u
k
ae
m
ia
;
C
M
L
,
ch
ro
n
ic
m
ye
lo
id
le
u
k
ae
m
ia
;
C
N
S,
ce
n
tr
al
n
e
rv
o
u
s
sy
st
e
m
;
C
R
,
co
m
p
le
te
re
m
is
si
o
n
;
F,
fe
m
al
e
;
G
M
,
ga
la
ct
o
m
an
n
an
;
H
L
A
,
h
u
m
an
le
u
k
o
cy
te
an
ti
ge
n
;
H
SC
T
,
h
ae
m
at
-
o
p
o
ie
ti
c
al
lo
ge
n
ei
c
st
e
m
ce
ll
tr
an
sp
la
n
ta
ti
o
n
;
M
,
m
al
e
;
M
D
S,
m
ye
lo
d
ys
p
la
st
ic
sy
n
d
ro
m
e
;
R
-D
H
A
P
,
ri
tu
x
im
ab
,
d
e
x
am
e
th
as
o
n
e,
cy
ta
ra
b
in
e
,
ci
sp
la
ti
n
;
R
IC
,
re
d
u
ce
d
-i
n
te
n
si
ty
co
n
d
it
io
n
in
g.
590 Clinical Microbiology and Infection, Volume 17 Number 4, April 2011 CMI
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 588–594
No claim to original US government works
pseudotumour. Two patients had extensive inﬂammatory,
ulcerative lesions of the stomach and duodenum. Culture of
the tissue was performed in 13 cases, and gave positive ﬁnd-
ings in 11, yielding Aspergillus fumigatus (n = 10) or Aspergillus
ﬂavus (n = 1). GM antigenaemia testing was performed in 20
cases, and gave a positive ﬁnding at least once in 16 patients
(median index of 3.3), including eight patients of the 11 with
a positive culture. Five patients (patients 1, 6, 9, 14, and 21)
had transient positivity of stool cultures for Aspergillus,
but this was not considered to be a diagnostic criterion. In
three of these ﬁve patients, both gut biopsy and stools grew
A. fumigatus. Six patients were diagnosed with gut aspergillo-
sis only after death, in four of them after a prolonged history
of unexplained gut symptoms: ﬁve at autopsy, and in one
case after the patient had died during surgery (patient 3).
All of these six patients had received empirical antifungal
therapy with deoxycholate amphotericin B or caspofungin
for 1–10 days before they died.
All patients diagnosed before death received antifungal
agents, mostly voriconazole (n = 8) or liposomal amphoteri-
cin B (n = 4), for ﬁrst-line treatment, and for 2–7 months
after diagnosis. Four patients received combinations of anti-
fungals at some point in their treatment. Twelve patients
were operated on, ten for both diagnosis and therapeutic
purposes, and two for fungal resection when the aetiologic
diagnosis was already known before surgery. Six of them
died. Nine of these 12 patients were operated on while they
were neutropenic.
According to the criteria of Segal et al. [7], excluding the
six patients diagnosed post-mortem, eight of the 15 remain-
ing patients (53%) survived at 12 weeks; six had a complete
response, one had partial response, and one was not evalu-
able. Seven of the 12 patients who underwent surgery died,
as compared with six of the nine patients who did not. Of
the eight patients with isolated gut aspergillosis, excluding
patient 4, who died in the operating theatre, ﬁve underwent
surgery, and three of these ﬁve died later. Ten of the 13
patients with disseminated aspergillosis died at 12 weeks;
one additional patient (patient 5) who was alive at 12 weeks
died 4 weeks later.
As the three Creteil patients were from the French Carib-
bean, Commores, and Africa, and we never saw any case in
Caucasian patients, we looked at the ethnic and geographical
origin of the patients from other centres, hypothesizing that
a non-European origin could be associated with special food,
rich in spices [10]. Three patients (patients 3, 4, and 5) were
either from Africa, the Paciﬁc Ocean or the Antilles; one
French woman (patient15) had eaten a purely African diet
for 10 years; and patient 2 had been living in Tahiti for
(a)
(b)
FIG. 2. (a) Haematoxylin and eosin-stained histological section
(·1.25 original magniﬁcation) obtained after right hemi-colonectomy
of patient 4, showing an abscess with mucosal disruption. Numerous
hyphae compatible with Aspergillus were seen in the abscess with
additional staining and higher magniﬁcation. (b) Intestinal section
obtained after right hemi-colonectomy of patient 4, showing Aspergillus
hyphae (Gomori–Grocott staining; magniﬁcation ·40).
FIG. 1. Abdominal computed tomography scan of patient 4 showing
a heterogeneous mass containing liquid in the wall of the colon.
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2 years before the diagnosis of gut IA. Four of these ﬁve
patients had isolated gut lesions.
Discussion
The gut is a very rare location of IA in the literature. In the
exhaustive review by Eggiman et al. [5], it accounted for
5.5% of 1538 cases of aspergillosis. Most cases were
observed in disseminated disease; isolated gut aspergillosis
was very exceptional (0.8%) [5]. However, considering the
higher incidence rate in autopsy series [2,11–14], it is likely
that the diagnosis is underestimated before death, owing to
the poor speciﬁcity of the clinical symptoms and imaging.
This is also supported by the fact that ﬁve of our 21 patients
were diagnosed only at autopsy.
Our series is the largest series of gut aspergillosis so far
reported. The retrospective design of this study precluded
the possibility of systematic investigative procedures and
treatments. However, some main ﬁndings emerge from our
series.
First, we were unable to ﬁnd any characteristic clinical or
imaging features of gut aspergillosis. As most gut symptoms
result from necrotic lesions, obstruction or haemorrhage, it
is likely that there is no characteristic clinical presentation or
imaging for such lesions. Most of the symptoms would have
oriented the clinician to a bacterial complication with typhli-
tis, or neutropenic enterocolitis that may have preceded the
gut lesions and favoured yeast colonization on an altered
mucosa, through mucositis favoured by high-dose aracytine
or gut graft-versus-host disease. Many patients may therefore
have been given antibacterials and gut aspiration without any
other treatment. However, in two cases, the abdominal CT
scan showed images of masses or abscesses (Fig. 1) leading
to surgery on the assumption of a bacterial or tumoral
lesion. In other cases, the occurrence of an acute, severe
complication, such as occlusion, or peritonitis, could have
driven the decision to operate in these very critical patients.
In our series, the lower gastrointestinal tract (small bowel,
colon, and rectum) appears to be more frequently involved
(17/21) than the upper gastrointestinal tract (oesophagus and
stomach) (9/21), although ﬁve of our patients had concomi-
tant upper and lower involvement, but this may be biased by
the absence of a common diagnostic strategy. Some of these
localizations, especially of the small bowel, are usually not
accessible by endoscopy; surgery is usually needed for early
diagnosis.
Second, gut aspergillosis can occur either in an isolated
site or, more frequently, in the setting of a disseminated
aspergillosis. The prognosis in the setting of disseminated
aspergillosis is extremely poor and consistent with previous
series reporting patients with multiple localizations of infec-
tion [14,15]. Because autopsy has not been systematically
performed, we cannot deﬁnitely exclude other concomitant
localizations in the patients who were considered to have
‘isolated’ gut lesions. However, all but one of the patients
had a chest CT scan performed, which did not indicate any
lung lesion. This small group of eight patients with isolated
gut aspergillosis suggests that the hypothesis of a digestive
(instead of respiratory) portal of entry is reasonable. It sug-
gests either recent ingestion of food that is highly contami-
nated with Aspergillus, or chronic low-burden ingestion with
asymptomatic gut colonization, which becomes clinically
manifest in conditions of immunosuppression and mucositis.
These cases could be real cases of ‘primary’ gut aspergillo-
sis, where the gut is the portal of entry and there are local
invasive lesions, but the infection does not disseminate.
This hypothesis is supported by a historical publication that
reported contamination of food with Aspergillus spp. from
pepper in the setting of an Aspergillus outbreak in a trans-
plant ward [10]. It should be noted that ﬁve of our
patients—and four of the eight patients with isolated gut
aspergillosis—habitually ate food that was extremely rich in
spices.
Third, a major point is that four of the eight patients with
isolated gut aspergillosis had a positive serum GM antigena-
emia test ﬁnding; two of them (patients 3 and 6) had an
index >4, with no evidence of respiratory lesion. Therefore,
before a GM antigenaemia test ﬁnding is regarded as being
false-positive, the possibility of gut aspergillosis should cer-
tainly be considered in at-risk patients presenting with
abdominal symptoms. In the revised version of the EORTC-
MSG criteria, there is no deﬁnition of probable gut aspergil-
losis [6]. Therefore, we selected only proven cases.
Although it would be extremely difﬁcult to establish a rela-
tionship between a positive serum GM antigenaemia test
ﬁnding and gut symptoms in such immunocompromised
patients, we would like to emphasize that the persistence of
a positive GM antigenaemia test ﬁnding that is not explained
by a lung or sinus lesion should lead to an exhaustive search
for its origin, including a gut localization, before being con-
sidered to be false-positive. Taking in account an unex-
plained GM antigenaemia test ﬁnding is even more
important if one considers the poor speciﬁcity of clinical
symptoms and of imaging. The clinical signiﬁcance of the
presence of Aspergillus spp. in stool samples cannot be deter-
mined from our study.
Fourth, when serial GM antigenaemia tests were per-
formed, we found a good relationship between the evolu-
tion of the GM antigenaemia test ﬁndings over time under
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treatment and the ﬁnal outcome, as in other localizations of
aspergillosis [16,17]. Among the 16 patients who had a posi-
tive GM antigenaemia test ﬁnding at diagnosis, treatment led
to a normalization in a mean time of 57 days (range: 7–
160 days) in seven patients, and all but one were alive at
12 weeks. In contrast, the nine patients whose GM antigena-
emia test ﬁndings remained positive under treatment for a
mean time of 20 days (range: 2–79 days) died before the
12th week after diagnosis.
The optimal treatment and the respective contribution of
surgery vs. antifungals cannot be clearly stated. Antifungals
should certainly be administered, preferably intravenously.
When surgery is decided on for diagnostic purposes, this is
also a good opportunity to reduce the fungal burden, at the
same time as dealing with other possible complications. The
beneﬁt of surgery to remove the gut lesion should logically
be higher—perhaps curative—in isolated than in dissemi-
nated forms. When the diagnosis has already been made,
surgery in the absence of severe complications (perforation
and haemorrhage) should certainly be cautiously considered,
especially in disseminated forms and when the patient is dee-
ply neutropenic.
Conclusion
The gut seems to be an exceptional site of Aspergillus infec-
tion in haematology patients. The diagnosis is extremely difﬁ-
cult in the absence of surgical investigation, owing to the
poor speciﬁcity of the symptoms and the absence of charac-
teristic imaging. The overall mortality rate was 57% in the
patients of our series. Patients with a positive GM antigena-
emia test ﬁnding that is unexplained by respiratory lesions
should be suspected of having gut aspergillosis in the pres-
ence of abdominal symptoms. Diagnostic procedures should
be performed without delay. Haematologists have to be
aware of this complication, whose frequency may be under-
estimated. In most cases, it seems logical to combine medical
and surgical therapy. However, the optimal therapy is so far
not established.
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